AWT Labels and Packaging has acquired US-based Citation Clinical Labeling Systems, which provides clinical trial labels for pharmaceutical and biotechnology companies, for an undisclosed sum.

Following the acquisition, Citation Clinical Labeling business, which will be owned by AWT and management, will now operate as Citation Healthcare Labels.

Citation president Richard Bolnick and chief operating officer Frederick Youngs will continue in their respective roles as well as will become shareholders of AWT.

The company also offers clinical trial labels for clinical research organisations and clinical packagers. It provides product quality, project management, customer service and speed to market services for pharmaceutical customers.

Citation currently operates from a single pharmaceutical and medical grade facility in Hauppauge, New York and employs approximately 100 employees.

Bolnick said: “Citation looks forward to the next chapter of growth by joining the AWT organisation.

“We believe the best is yet to come for our customers as they will benefit from additional facilities, personnel and resources of the combined businesses.”

“Citation and AWT share many of the same philosophies including providing our customers with a world-class experience, a commitment to healthcare labelling and quality systems, the development of our employees and continually investing in state-of-the-art equipment.

“We believe the best is yet to come for our customers as they will benefit from additional facilities, personnel and resources of the combined businesses.”

The deal strengthens AWT’s presence in healthcare labelling market globally, and enable it to benefit from the growth opportunities in the clinical trial label markets.

As part of the deal, Citation customers can now access AWT’s resources and investments in print and production technologies and its healthcare labelling plant in Minneapolis.

Free Whitepaper How electronic inspection sensors prevented a potentially extremely costly product recall

A pharmaceutical client was at risk of a product recall due to a capping problem with a new tablet formulation. This document explains how DJA Pharma prevented a costly recall with a simple, elegant and effective solution.

Enter your details here to receive your free whitepaper.

Machinery whitepaper

Download our whitepaper

Yes I have read and accept the terms and conditions and privacy policys.


You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our Verdict Privacy Policy to see how we protect and manage your submitted data.

You will receive your free whitepaper after you submit the form.

Close